What is Geron?
Geron is dedicated to the development and potential commercialization of imetelstat, a novel therapeutic agent for blood cancers. The company is currently advancing two pivotal Phase 3 clinical trials: IMerge, focusing on lower-risk myelodysplastic syndromes, and IMpactMF, investigating refractory myelofibrosis. This strategic focus positions Geron at the forefront of innovative treatments for challenging hematologic conditions.
How much funding has Geron raised?
Geron has raised a total of $466M across 3 funding rounds:
Stock Offering
$16M
Debt
$75M
Debt
$375M
Stock Issuance/Offering (1996): $16M, investors not publicly disclosed
Debt (2020): $75M led by Hercules Capital and Silicon Valley Bank
Debt (2024): $375M supported by Royalty Pharma
Key Investors in Geron
Royalty Pharma
Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation, collaborating with various entities from academic institutions to leading global pharmaceutical companies. They fund innovation by partnering to co-fund late-stage clinical trials and new product launches in exchange for future royalties, or by acquiring existing royalties.
Hercules Capital
Hercules Capital is a specialty finance company providing senior secured venture growth loans to high-growth, innovative venture capital-backed companies across technology, life sciences, and sustainable/renewable technology industries.
Silicon Valley Bank
Silicon Valley Bank offers a comprehensive suite of financial services including commercial and private banking, asset management, private wealth management, brokerage & investment services, funds management, and business valuation services.
What's next for Geron?
The recent major strategic investment signals a critical juncture for Geron, likely enabling the acceleration of its late-stage clinical development programs and preparing for potential commercialization. This capital infusion is expected to bolster the company's efforts in bringing imetelstat to patients suffering from myelodysplastic syndromes and myelofibrosis, marking a significant step towards achieving its long-term growth objectives.
See full Geron company page
